NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03777657,"Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma",https://clinicaltrials.gov/study/NCT03777657,,COMPLETED,This study was designed to compare the efficacy and safety of tislelizumab plus chemotherapy versus placebo plus chemotherapy as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.,YES,"Gastric, or Gastroesophageal Junction Adenocarcinoma",DRUG: Tislelizumab|DRUG: Placebo|DRUG: Cisplatin|DRUG: Oxaliplatin|DRUG: Capecitabine|DRUG: 5-Fluorouracil,"Overall Survival in PD-L1 Positive Participants, Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method., From randomization up to the primary analysis data cut-off date of 8 October 2021; Median (range) time on follow-up was 11.8 (0.1 - 33.4) months.|Overall Survival in the Intent-to-Treat (ITT) Analysis Set, Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method., From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.","Progression-free Survival (PFS) in PD-L1 Positive Participants, Progression-free survival is defined as the time from the date of randomization to the date of the first objectively documented tumor progression assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death, whichever occurred first.

Median PFS was estimated using the Kaplan-Meier method., From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.|Overall Response Rate (ORR) in PD-L1 Positive Participants, ORR is defined as the percentage of participants whose best overall response is complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors v1.1 assessed by the investigator.

Investigators conducted assessments of radiological tumor response by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter.

CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm.

PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits., Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.|Progression-free Survival (PFS) in the ITT Analysis Set, Progression-free survival is defined as the time from the date of randomization to the date of the first objectively documented tumor progression assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death, whichever occurred first.

Median PFS was estimated using the Kaplan-Meier method., From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.|Overall Response Rate (ORR) in the ITT Analysis Set, ORR is defined as the percentage of participants whose best overall response is complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors v1.1 assessed by the investigator.

Investigators conducted assessments of radiological tumor response by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter.

CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm.

PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits., Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.|Duration of Response (DOR) in PD-L1 Positive Participants, DOR is defined as the time from the first determination of an objective response assessed by the investigator per RECIST v1.1, until the first documentation of progression or death, whichever occurred first.

Progressive disease (PD): At least a 20% increase in the size of target lesions, taking as reference the smallest size on study, with an absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or any new lesions., Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.|Duration of Response in the ITT Analysis Set, DOR is defined as the time from the first determination of an objective response assessed by the investigator per RECIST v1.1, until the first documentation of progression or death, whichever occurred first.

Progressive disease (PD): At least a 20% increase in the size of target lesions, taking as reference the smallest size on study, with an absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or any new lesions., Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.|Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) and Physical Functioning Scores, The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life., Baseline and Cycles 4 and 6|Change From Baseline in EORTC QLQ-C30 Fatigue Score, The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. The fatigue symptom scale includes 3 items and ranges from 0 to 100, where higher scores indicate a higher level of symptoms., Baseline and Cycles 4 and 6|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Gastric Cancer Module QLQ-STO22 (EORTC QLQ-STO22), EORTC-QLQ-STO22 is a 22-item questionnaire developed to assess QoL of gastric cancer participants. It consists of 5 multi-item subscales: Dysphagia/odynophagia (4 items), Pain/discomfort (3 items), Dietary restrictions (5 items), Upper gastro-intestinal (GI) symptoms (3 items), Specific emotional problems (3 items) and 4 single items. Each question is answered on a scale from 0 (Not at all) to 4 (Very Much), where lower scores indicate fewer symptoms/better QoL.

Raw scores were transformed to a scale from 0 to 100, where lower scores indicate better QoL.

The QLQ-STO22 Index score is the mean of the 6 domain scores and 4 single items., Baseline and Cycles 4 and 6|Change From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS), The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes., Baseline and Cycles 4 and 6|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drugs, whether related to study drugs or not.

An SAE is any untoward medical occurrence that, at any dose met any of the following criteria:

* Resulted in death
* Was life-threatening
* Required hospitalization or prolongation of existing hospitalization
* Resulted in disability/incapacity
* Was a congenital anomaly/birth defect
* Was considered a significant medical AE by the Investigator based on medical judgement., From first dose of study drug to 30 days after last dose or the initiation of a new anticancer therapy, whichever occurred first, up to the end of study; maximum treatment duration was 59.3 months in Tislelizumab and 56.8 months in the Placebo group.|Disease Control Rate in PD-L1 Positive Participants, Disease Control Rate is defined as the percentage of participants who had confirmed CR, PR, or stable disease (SD) assessed by the investigator and the investigator per RECIST v1.1. Investigators conducted assessments of radiological tumor response by CT or MRI per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter.

CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm.

PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.

SD: Neither sufficient shrinkage in size of lesions to qualify for PR nor sufficient increase to qualify for PD, and no new lesions., Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.|Disease Control Rate in the ITT Analysis Set, Disease Control Rate is defined as the percentage of participants who had confirmed CR, PR, or stable disease (SD) assessed by the investigator per RECIST v1.1. Investigators conducted assessments of radiological tumor response by CT or MRI per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter.

CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm.

PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.

SD: Neither sufficient shrinkage in size of lesions to qualify for PR nor sufficient increase to qualify for PD, and no new lesions., Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.|Clinical Benefit Rate (CBR) in PD-L1 Positive Participants, Clinical benefit rate is defined as the percentage of participants who achieved a confirmed complete response, partial response, or durable stable disease assessed by the Investigator per RECIST v1.1.

CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm.

PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.

Durable SD: Stable disease for ≥ 24 weeks., Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.|Clinical Benefit Rate (CBR) in the ITT Analysis Set, Clinical benefit rate is defined as the percentage of participants who achieved a confirmed complete response, partial response, or durable stable disease assessed by the Investigator per RECIST v1.1.

CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm.

PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.

Durable SD: Stable disease for ≥ 24 weeks., Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.|Time to Response (TTR) in PD-L1 Positive Participants, Time to response is defined as the time from randomization to the first determination of an objective response per RECIST version 1.1 as assessed by the investigator., From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.|Time to Response (TTR) in the ITT Analysis Set, Time to response is defined as the time from randomization to the first determination of an objective response per RECIST version 1.1 as assessed by the investigator., From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.",,BeiGene,,ALL,"ADULT, OLDER_ADULT",PHASE3,997,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",BGB-A317-305|2018-000312-24|CTR20181841|JapicCTI-194799,2018-12-13,2023-02-28,2024-08-27,2018-12-17,2025-03-25,2025-03-25,"University of California Davis Health System, Sacramento, California, 95817, United States|Southeastern Regional Medical Center, Newnan, Georgia, 30265, United States|Ohio State University Hospital, Columbus, Ohio, 43210, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Reading Hospital, West Reading, Pennsylvania, 19611, United States|Tennessee Oncology, Pllc Nashville, Nashville, Tennessee, 37203, United States|The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, 233004, China|Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital, Hefei, Anhui, 230088, China|The Second Hospital of Anhui Medical University, Hefei, Anhui, 230601, China|Peking University Third Hospital, Beijing, Beijing, 100000, China|Beijing Chao Yang Hospital, Beijing, Beijing, 100020, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, 100021, China|Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, 100050, China|Beijing Cancer Hospital, Beijing, Beijing, 100142, China|Peking Union Medical College Hospital, Beijing, Beijing, 100730, China|Chinese Pla General Hospital, Beijing, Beijing, 100853, China|Beijing Luhe Hospital, Capital Medical University, Beijing, Beijing, 101149, China|Daping Hospital, Third Military Medical University, Chongqing, Chongqing, 400042, China|The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, 350005, China|Fujian Cancer Hospital, Fuzhou, Fujian, 350014, China|The First Hospital of Lanzhou University, Lanzhou, Gansu, 730000, China|Foshan First Peoples Hospital, Foshan, Guangdong, 528000, China|Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, 510060, China|Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, 510080, China|Shenzhen Peoples Hospital, Shenzhen, Guangdong, 518020, China|Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, 541001, China|Hainan General Hospital, Haikou, Hainan, 570206, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150000, China|Henan Cancer Hospital, Zhengzhou, Henan, 450000, China|Henan Provincial Peoples Hospital, Zhengzhou, Henan, 450003, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China|Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China|Hubei Cancer Hospital, Wuhan, Hubei, 430079, China|Xiangya Hospital of Central South University, Changsha, Hunan, 410008, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, 210008, China|Nantong Tumor Hospital Branch South, Nantong, Jiangsu, 226000, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China|The First Hospital of Jilin University, Changchun, Jilin, 130021, China|The First Hospital of China Medical University, Shenyang, Liaoning, 110001, China|The General Hospital of Shenyang Military, Shenyang, Liaoning, 110016, China|Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, 110042, China|Shandong Cancer Hospital, Jinan, Shandong, 250117, China|Linyi Cancer Hospital, Linyi, Shandong, 276001, China|The Affiliated Hospital of Qingdao University Branch South, Qingdao, Shandong, 266000, China|Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200025, China|Affiliated Zhongshan Hospital of Fudan University, Shanghai, Shanghai, 200032, China|Shanghai General Hospital, Shanghai, Shanghai, 200080, China|Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200092, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, 300052, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, 300060, China|Yunnan Cancer Hospital, Kunming, Yunnan, 650100, China|The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China|Zhejiang University College of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, 310009, China|Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310016, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|Centre Georges Francois Leclerc, Dijon, 21079, France|Chu Besancon Hopital Jean Minjoz, Doubs, 25030, France|Hopital de La Timone, Marseille, 13005, France|Icl Alexis Vautrin, Meurthe Et Moselle, 54519, France|Hopital Nord Franche Comte Site Du Mittan, Montbeliard, 25200, France|Centre Antoine Lacassagne, Nice, 06100, France|Chu Bordeaux Hopital Haut Leveque, Pessac, 33600, France|Azienda Ospedaliera Universitaria Policlinico Santorsola Malpighi, Bologna, 40138, Italy|Fondazione Irccs Istituto Nazionale Dei Tumori, Milano, 20133, Italy|Istituto Nazionale Tumori Fondazione G Pascale, Napoli, 80131, Italy|Iov Istituto Oncologico Veneto Irccs, Padova, 35128, Italy|Ao Ospedali Riuniti Marche Nord, Pesaro, 61122, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, 56126, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, 133, Italy|Irccs Ospedale Casa Sollievo Della Sofferenza, San Giovanni Rotondo, 71013, Italy|Aou Senese Policlinico Santa Maria Alle Scotte, Siena, 53100, Italy|Azienda Ospedaliera Citta Della Salute E Della Scienza Di Torino, Torino, 10126, Italy|Azienda Ospedaliera Universitaria Delle Marche, Torrette, 60020, Italy|Chiba Cancer Center, Chibashi, Chiba, 260-8717, Japan|Tesshokai Kameda General Hospital, Kamogawashi, Chiba, 296-8602, Japan|Nho Shikoku Cancer Center, Matsuyamashi, Ehime, 791-0280, Japan|Nho Kyushu Cancer Center, Fukuokashi, Fukuoka, 811-1395, Japan|Gunma Prefectural Cancer Center, Otashi, Gunma, 373-8550, Japan|Hokkaido University Hospital, Sapporoshi, Hokkaido, 060-8648, Japan|Johas Kansai Rosai Hospital, Amagasakishi, Hyogo, 660-8511, Japan|Ishikawa Prefectural Central Hospital, Kanazawashi, Ishikawa, 920-8530, Japan|Kagawa University Hospital, Kitagun, Kagawa, 761-0793, Japan|Kanagawa Cancer Center, Yokohamashi, Kanagawa, 241-8515, Japan|Oita University Hospital, Yufushi, Oita, 879-5593, Japan|Kurashiki Central Hospital, Kurashikishi, Okayama, 710-8602, Japan|Okayama University Hospital, Okayamashi, Okayama, 700-8558, Japan|Izumi City General Hospital, Izumishi, Osaka, 594-0073, Japan|Nho Osaka National Hospital, Osakashi, Osaka, 540-0006, Japan|Osaka University Hospital, Suitashi, Osaka, 565-0871, Japan|Saitama Medical University International Medical Center, Hidakashi, Saitama, 350-1298, Japan|Saitama Cancer Center, Kitaadachigun, Saitama, 362-0806, Japan|Hamamatsu University School of Medicine, University Hospital, Hamamatsushi, Shizuoka, 431-3192, Japan|National Cancer Center Hospital, Chuoku, Tokyo, 104-0045, Japan|Tokyo Metropolitan Tama Medical Center, Fuchushi, Tokyo, 183-8524, Japan|Cancer Institute Hospital of Jfcr, Kotoku, Tokyo, 135-8550, Japan|Center Hospital of the National Center For Global Health and Medicine, Shinjukuku, Tokyo, 162-8655, Japan|National Cancer Center, Goyangsi, Gyeonggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital, Seongnamsi, Gyeonggi-do, 13620, Korea, Republic of|The Catholic University of Korea, St Vincents Hospital, Suwonsi, Gyeonggi-do, 16247, Korea, Republic of|Ajou University Hospital, Suwonsi, Gyeonggi-do, 16499, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Gyeongsangbukdo, 41404, Korea, Republic of|Chonnam National University Hwasun Hospital, HwasunGun, Jeollanam-do, 58128, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, 03080, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Seoul Teugbyeolsi, 03722, Korea, Republic of|Asan Medical Center, Seoul, Seoul Teugbyeolsi, 05505, Korea, Republic of|Chung Ang University Hospital, Seoul, Seoul Teugbyeolsi, 6973, Korea, Republic of|Uniwersyteckie Centrum Kliniczne, Gdansk, 80-952, Poland|Centrum Terapii Wspolczesnej Jm Jasnorzewska Sp Komandytowo Akcyjna, Lodz, 90-242, Poland|Przychodnia Med Polonia Sp Z Oo, Poznan, 60-693, Poland|Narodowy Instytut Onkologii Im Marii Skodowskiej Curie Pastwowy Instytut Badawczy, Warszawa, 02-034, Poland|Pan American Oncology Trials, Llc, Rio Piedras, 00935, Puerto Rico|Arkhangelsk Regional Clinical Oncological Dispensary, Arkhangelsk, Arkhangel'skaya Oblast', 163045, Russian Federation|Rbih Ivanovo Regional Oncological Dispensary, Ivanovo, Ivanovskaya Oblast', 153040, Russian Federation|Vitamed Llc, Moscow, Moskva, 121309, Russian Federation|Sbhi of Novosibirsk Region Novosibirsk Regional Oncological Dispensary, Novosibirsk, Novosibirskaya Oblast', 630108, Russian Federation|Bih of Omsk Region Clinical Oncology Dispensary, Omsk, Omskaya Oblast', 644013, Russian Federation|Private Educational Institution of Higher Education Medical University Reaviz, Samara, Samaraskaya Oblast', 443011, Russian Federation|Pavlov First Saint Petersburg State Medical University, SaintPetersburg, Sankt-Peterburg, 197022, Russian Federation|Fsbi Clinical Research and Practical Center For Specialized Medical Care (Oncology), SanktPetersburg, Sankt-Peterburg, 197758, Russian Federation|State Budgetary Healthcare Institution Volgograd Regional Clinical Oncology Dispensary, Volgograd, Volgogradskaya Oblast', 400138, Russian Federation|Sbih of Yaroslavl Region Regional Clinical Oncological Hospital, Yaroslavl, Yaroslavskaya Oblast', 150054, Russian Federation|Hospital Clinic de Barcelona, Barcelona, 8036, Spain|Hospital de Basurto, Bilbao, 48013, Spain|Hospital General Universitario de Elche, Elche, 3203, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28007, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Universitario Hm Madrid Sanchinarro, Madrid, 28050, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, 28222, Spain|Hospital Regional Universitario de Malaga, Malaga, 29010, Spain|Complejo Hospitalario de Navarra, Pamplona, 31008, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, 41013, Spain|Hospital Clinico Universitario de Valencia, Valencia, 46010, Spain|Initia Oncologia, Slp, Valencia, 46010, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain|Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, 807, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Acibadem Adana Hospital, Adana, 01130, Turkey|Dr Abdurrahman Yurtaslan Oncology Teaching and Research Hospital, Ankara, 06620, Turkey|Nonu Universitesi Tip Fakultesi, Battalgazi, 44280, Turkey|Dicle University Medical Faculty, Diyarbakir, 21080, Turkey|Akdeniz University Hospital, Konyaalt, 07070, Turkey|Iu C, Clinical Research Excellence Application and Research Center, Stanbul, 34098, Turkey|Namik Kemal University, Tekirdag, 59100, Turkey|Karadeniz Tecnical Uni Med Fac, Trabzon, 61080, Turkey|Velindre Cancer Centre, Cardiff, CF14 2TL, United Kingdom|Sarah Cannon Research Institute Uk, London, W1G 6AD, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/57/NCT03777657/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/57/NCT03777657/SAP_001.pdf"
